5-fluorouridine is also known as FUrd, 5-Fluorouracil 1-beta-D-ribofuranoside, 5-Fur, or 5-Fluoro-uridine. 5-fluorouridine is a solid. This compound belongs to the pyrimidine nucleosides and analogues. These are compounds comprising a pyrimidine base attached to a sugar. 5-fluorouridine is known to target uridine phosphorylase. FUrd is often used in chemical and biochemical comparison studies with fluorouracil and thymine analogs.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Cimetidine | The serum concentration of 5-fluorouridine can be increased when it is combined with Cimetidine. |
| Gemcitabine | The serum concentration of 5-fluorouridine can be increased when it is combined with Gemcitabine. |
| Sorafenib | The risk or severity of QTc prolongation can be increased when Sorafenib is combined with 5-fluorouridine. |
| Phenytoin | The serum concentration of Phenytoin can be increased when it is combined with 5-fluorouridine. |
| Fosphenytoin | The serum concentration of Fosphenytoin can be increased when it is combined with 5-fluorouridine. |
| Gimeracil | The serum concentration of 5-fluorouridine can be increased when it is combined with Gimeracil. |
| Metronidazole | The serum concentration of 5-fluorouridine can be increased when it is combined with Metronidazole. |
| Methotrexate | The risk or severity of adverse effects can be increased when Methotrexate is combined with 5-fluorouridine. |
| Dicoumarol | The risk or severity of bleeding can be increased when 5-fluorouridine is combined with Dicoumarol. |
| Phenindione | The risk or severity of bleeding can be increased when 5-fluorouridine is combined with Phenindione. |
| Warfarin | The risk or severity of bleeding can be increased when 5-fluorouridine is combined with Warfarin. |
| Phenprocoumon | The risk or severity of bleeding can be increased when 5-fluorouridine is combined with Phenprocoumon. |
| Acenocoumarol | The risk or severity of bleeding can be increased when 5-fluorouridine is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of bleeding can be increased when 5-fluorouridine is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of bleeding can be increased when 5-fluorouridine is combined with Coumarin. |
| (R)-warfarin | The risk or severity of bleeding can be increased when 5-fluorouridine is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of bleeding can be increased when 5-fluorouridine is combined with Ethyl biscoumacetate. |
| Fluindione | The risk or severity of bleeding can be increased when 5-fluorouridine is combined with Fluindione. |
| Clorindione | The risk or severity of bleeding can be increased when 5-fluorouridine is combined with Clorindione. |
| Diphenadione | The risk or severity of bleeding can be increased when 5-fluorouridine is combined with Diphenadione. |
| Tioclomarol | The risk or severity of bleeding can be increased when 5-fluorouridine is combined with Tioclomarol. |
| (S)-Warfarin | The risk or severity of bleeding can be increased when 5-fluorouridine is combined with (S)-Warfarin. |
| Sunitinib | The risk or severity of QTc prolongation can be increased when 5-fluorouridine is combined with Sunitinib. |
| Tetrahydrofolic acid | The risk or severity of adverse effects can be increased when Tetrahydrofolic acid is combined with 5-fluorouridine. |
| Folic acid | The risk or severity of adverse effects can be increased when Folic acid is combined with 5-fluorouridine. |
| Leucovorin | The risk or severity of adverse effects can be increased when Leucovorin is combined with 5-fluorouridine. |
| (6S)-5,6,7,8-tetrahydrofolic acid | The risk or severity of adverse effects can be increased when (6S)-5,6,7,8-tetrahydrofolic acid is combined with 5-fluorouridine. |
| Triglu-5-formyl-tetrahydrofolate | The risk or severity of adverse effects can be increased when Triglu-5-formyl-tetrahydrofolate is combined with 5-fluorouridine. |
| (6R)-Folinic acid | The risk or severity of adverse effects can be increased when (6R)-Folinic acid is combined with 5-fluorouridine. |
| 5-methyltetrahydrofolic acid | The risk or severity of adverse effects can be increased when 5-methyltetrahydrofolic acid is combined with 5-fluorouridine. |
| Levomefolic acid | The risk or severity of adverse effects can be increased when Levomefolic acid is combined with 5-fluorouridine. |
| Levoleucovorin | The risk or severity of adverse effects can be increased when Levoleucovorin is combined with 5-fluorouridine. |
| Liothyronine | The therapeutic efficacy of Liothyronine can be decreased when used in combination with 5-fluorouridine. |
| Levothyroxine | The therapeutic efficacy of Levothyroxine can be decreased when used in combination with 5-fluorouridine. |
| Mephenytoin | The therapeutic efficacy of Mephenytoin can be decreased when used in combination with 5-fluorouridine. |
| Carbamazepine | The therapeutic efficacy of Carbamazepine can be decreased when used in combination with 5-fluorouridine. |
| Furosemide | The therapeutic efficacy of Furosemide can be decreased when used in combination with 5-fluorouridine. |
| Nitrofurantoin | The therapeutic efficacy of Nitrofurantoin can be decreased when used in combination with 5-fluorouridine. |
| Ethotoin | The therapeutic efficacy of Ethotoin can be decreased when used in combination with 5-fluorouridine. |
| Meclofenamic acid | The therapeutic efficacy of Meclofenamic acid can be decreased when used in combination with 5-fluorouridine. |
| Heparin | The therapeutic efficacy of Heparin can be decreased when used in combination with 5-fluorouridine. |
| Dantrolene | The therapeutic efficacy of Dantrolene can be decreased when used in combination with 5-fluorouridine. |
| Liotrix | The therapeutic efficacy of Liotrix can be decreased when used in combination with 5-fluorouridine. |
| Etofenamate | The therapeutic efficacy of Etofenamate can be decreased when used in combination with 5-fluorouridine. |
| Liothyronine I-131 | The therapeutic efficacy of Liothyronine I-131 can be decreased when used in combination with 5-fluorouridine. |
| Neocitrullamon | The therapeutic efficacy of Neocitrullamon can be decreased when used in combination with 5-fluorouridine. |
| Allantoin | The therapeutic efficacy of Allantoin can be decreased when used in combination with 5-fluorouridine. |